Rezurock Side Effects
Generic name: belumosudil
Medically reviewed by Drugs.com. Last updated on Sep 6, 2022.
Note: This document contains side effect information about belumosudil. Some dosage forms listed on this page may not apply to the brand name Rezurock.
Applies to belumosudil: oral tablet.
Serious side effects of Rezurock
Along with its needed effects, belumosudil (the active ingredient contained in Rezurock) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking belumosudil:
- Black, tarry stools
- bladder pain
- bloody nose
- bloody or cloudy urine
- bluish lips or skin
- blurred vision
- body aches or pain
- burning, dry or itching eyes
- chest pain or tightness
- collection of blood under the skin
- cough producing mucus
- deep, dark purple bruise
- difficult, burning, or painful urination
- discharge, excessive tearing
- ear congestion
- fast heartbeat
- frequent urge to urinate
- itching, pain, redness, or swelling
- loss of appetite
- loss of voice
- lower back or side pain
- muscle or bone pain
- pain or tenderness around the eyes and cheekbones
- pale skin
- pounding in the ears
- redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
- sore throat
- stomach pain
- stuffy or runny nose
- swelling of the hands, ankles, feet, or lower legs
- swelling or puffiness of the face
- trouble breathing
- unusual bleeding or bruising
- unusual tiredness or weakness
- watery and severe diarrhea, which may also be bloody
Other side effects of Rezurock
Some side effects of belumosudil may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Cracks in the skin
- difficulty in moving
- difficulty swallowing
- lack or loss of strength
- loss of heat from the body
- muscle pain, stiffness, or spasm
- pain in the joints
- rash with flat lesions or small raised lesions on the skin
- red, swollen, or scaly skin
For Healthcare Professionals
Applies to belumosudil: oral tablet.
Very common (10% or more): Neutrophil count decreased (83%), platelets decreased (82%), hemoglobin decreased (79%), lymphocytes decreased (62%)[Ref]
Very common (10% or more): Infection (unspecified pathogen) (e.g., acute sinusitis, device related infection, ear infection, folliculitis, gastroenteritis, GI infection, hordeolum, infectious colitis, lung infection, skin infection, tooth infection, urinary tract infection, wound infection, upper respiratory tract infection, pneumonia, conjunctivitis, sinusitis, respiratory tract infection, bronchitis, sepsis, septic shock) (53%), viral infection (e.g., influenza, rhinovirus infection, gastroenteritis viral, viral upper respiratory tract infection, bronchitis viral, Epstein-Barr viremia, Epstein-Barr virus infection, parainfluenzae virus infection, Varicella zoster virus infection, viral infection) (19%), bacterial infection (e.g., cellulitis, Helicobacter infection, Staphylococcal bacteremia, catheter site cellulitis, Clostridium difficile colitis, Escherichia urinary tract infection, gastroenteritis Escherichia coli, Pseudomonas infection, urinary tract infection bacterial) (16%)[Ref]
Very common (10% or more): Musculoskeletal (e.g., pain in extremity, back pain, flank pain, limb discomfort, musculoskeletal chest pain, neck pain, musculoskeletal pain) (22%), muscle spasm (17%), arthralgia (15%)[Ref]
Very common (10% or more): Anorexia (17%)[Ref]
Very common (10% or more): Gamma glutamyl transferase increased (47%)[Ref]
Very common (10% or more): Alkaline aminotransferase increased (83%), calcium decreased (82%), potassium increased (82%), alkaline phosphatase increased (80%), phosphate decreased (76%), asthenia/fatigue/malaise (46%), edema (e.g., edema peripheral, generalized edema, face edema, localized edema, edema) (27%), pyrexia (18%)[Ref]
The most common (20% or greater) adverse reactions, including laboratory abnormalities, were infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, and hypertension.
Adverse reactions leading to dose interruption occurred in 29% of patients. The adverse reactions leading to dose interruption in 2% or greater were infections (11%), diarrhea (4%), asthenia (2%), dyspnea (2%), hemorrhage (2%), hypotension (2%), liver function test abnormal (2%), nausea (2%), pyrexia (2%), edema (2%), and renal failure (2%).
Permanent discontinuation of this drug due to adverse reactions occurred in 18% of patients. The adverse reactions requiring discontinuation reported in greater than 3% of patients included nausea (4%).[Ref]
Very common (10% or more): Headache/migraine (21%)
Very common (10% or more): Creatinine increased (83%)[Ref]
Very common (10% or more): Hemorrhage (e.g., contusion, hematoma, epistaxis, increased tendency to bruise, conjunctival hemorrhage, hematochezia, mouth hemorrhage, catheter site hemorrhage, hematuria, hemothorax, purpura) (23%), hypertension (21%)[Ref]
More about Rezurock (belumosudil)
- Check interactions
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- En español
Related treatment guides
1. "Product Information. Rezurock (belumosudil)." Kadmon Pharmaceuticals (2021):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.